{
    "nct_id": "NCT05705401",
    "official_title": "A Phase III Randomized Trial of Radiotherapy Optimization for Low-Risk HER2-Positive Breast Cancer (HERO)",
    "brief_title": "Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer",
    "cancer_type_display": "A study for patients with early-stage, low-risk HER2-positive breast cancer who have undergone breast-conserving surgery.",
    "cancer_tags": [
      "HER2-positive Breast Cancer"
    ],
    "link_to_trial": "https://clinicaltrials.gov/study/NCT05705401",
    "phase": "Phase 3",
    "recruitment_status": "RECRUITING",
    "last_update_date": "2025-08-03",
    "enrollment": 1300,
    "min_age": 40,
    "max_age": null,
    "sex": "ALL",
    "is_metastatic_allowed": false,
    "performance_status_scale": "ECOG",
    "performance_status_values": [
      0,
      1,
      2
    ],
    "min_prior_lines": null,
    "max_prior_lines": null,
    "prior_treatments_required": [
      "Breast conserving surgery",
      "Minimum of 4 cycles (12 weeks) of neoadjuvant or adjuvant chemotherapy in combination with HER2-targeted therapy"
    ],
    "prior_treatments_excluded": [
      "Prior ipsilateral breast or thoracic RT for any condition",
      "Prior invasive breast malignancy"
    ],
    "principal_investigator": "Norman Wolmark, MD",
    "site_name": null,
    "contact_email": "langerj@nrgoncology.org",
    "contact_phone": "412-339-5300",
    "locations": null,
    "key_inclusion_summary": [
      "Must be 40 years of age or older.",
      "Patients must have undergone breast conserving surgery and completed at least 4 cycles of chemotherapy with HER2-targeted therapy.",
      "Histologically confirmed invasive, HER2-positive breast carcinoma.",
      "For the adjuvant cohort, the primary tumor must be â‰¤ 2 cm with negative nodes (pN0).",
      "For the neoadjuvant cohort, the primary tumor must be < 3 cm with clinically negative nodes (cN0) before treatment, and achieve a pathologic complete response (ypT0N0) after treatment."
    ],
    "key_exclusion_summary": [
      "Definitive clinical or radiologic evidence of metastatic disease.",
      "Pathologically positive axillary nodes.",
      "Patient is planning for or has already undergone a mastectomy.",
      "Multicentric carcinoma (cancer in more than one quadrant of the breast).",
      "Prior ipsilateral breast or thoracic radiotherapy for any condition."
    ]
  }